Polyunsaturated fatty acid supplementation for schizophrenia (Q24248708)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 22 April 2003)

Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia.
Polyunsaturated fatty acid supplementation for schizophrenia.

Language	Label	Description	Also known as
English	Polyunsaturated fatty acid supplementation for schizophrenia	scientific article (publication date: 22 April 2003)	Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia. Polyunsaturated fatty acid supplementation for schizophrenia.

Statements

scholarly article

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

Polyunsaturated fatty acid supplementation for schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

0 references

0 references

author name string

CB Joy

1

0 references

R Mumby-Croft

2

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

LA Joy

3

0 references

C B Joy

1

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

L A Joy

3

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

22 April 2003

0 references

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cochrane Database of Systematic Reviews

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

2

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

CD001257

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Corticosteroids in psychiatric patients: subacute and diurnal effects on free fatty acid and catecholamine metabolism.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Statistics notes. Trials randomised in clusters

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Fat consumption and schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Participation of prostaglandin E2 in dopamine D2 receptor-dependent potentiation of arachidonic acid release

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Fatty acid levels in the brains of schizophrenics and normal controls

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

The membrane hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Content and quality of 2000 controlled trials in schizophrenia over 50 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

21 January 2018

Fatty acids and schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

7 January 2021

based on heuristic

inferred from DOI database lookup

Schizophrenic symptoms and dietary intake of n-3 fatty acids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

7 January 2021

based on heuristic

inferred from DOI database lookup

Membrane fatty acids, niacin flushing and clinical parameters

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

7 January 2021

based on heuristic

inferred from DOI database lookup

Essential fatty acid supplementation in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001257

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD001257

2 references

Europe PubMed Central

PubMed publication ID

27 June 2017

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24248708&oldid=1609484394"